- Home
- MREO vs NTRB Comparison
MREO vs NTRB Comparison
Compare MREO & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MREO | NTRB |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | 3 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 44.2M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | MREO | NTRB |
|---|---|---|
| Price | $0.33 | $3.85 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 9.6K |
| Earning Date | 05-12-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | $6,000.20 | $30.17 |
| Revenue Next Year | $34.71 | $3,394.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $3.42 |
| 52 Week High | $2.94 | $11.68 |
Technical Indicators
Market Signals| Indicator | MREO | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 44.83 |
| Support Level | $0.32 | $3.51 |
| Resistance Level | $0.42 | $4.50 |
| Average True Range (ATR) | 0.02 | 0.26 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 42.31 | 40.31 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.